Standard
Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. / See, W; Iversen, P; Wirth, M; McLeod, D; Garside, L; Morris, T.
In:
European Urology, Vol. 44, No. 5, 2003, p. 512-7; discussion 517-8.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
See, W, Iversen, P, Wirth, M, McLeod, D, Garside, L & Morris, T 2003, 'Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer', European Urology, vol. 44, no. 5, pp. 512-7; discussion 517-8.
APA
See, W., Iversen, P., Wirth, M., McLeod, D., Garside, L., & Morris, T. (2003). Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology, 44(5), 512-7; discussion 517-8.
Vancouver
See W, Iversen P, Wirth M, McLeod D, Garside L, Morris T. Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. European Urology. 2003;44(5):512-7; discussion 517-8.
Author
See, W ; Iversen, P ; Wirth, M ; McLeod, D ; Garside, L ; Morris, T. / Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer. In: European Urology. 2003 ; Vol. 44, No. 5. pp. 512-7; discussion 517-8.
Bibtex
@article{fcca5f2f031a49e3b8b79001a27fb3a1,
title = "Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer",
abstract = "To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.",
author = "W See and P Iversen and M Wirth and D McLeod and L Garside and T Morris",
year = "2003",
language = "English",
volume = "44",
pages = "512--7; discussion 517--8",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",
}
RIS
TY - JOUR
T1 - Immediate treatment with bicalutamide 150mg as adjuvant therapy significantly reduces the risk of PSA progression in early prostate cancer
AU - See, W
AU - Iversen, P
AU - Wirth, M
AU - McLeod, D
AU - Garside, L
AU - Morris, T
PY - 2003
Y1 - 2003
N2 - To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.
AB - To evaluate the effect of bicalutamide ('Casodex') 150mg (in addition to standard care), on the risk of prostate-specific antigen (PSA) progression, in patients with early prostate cancer.
M3 - Journal article
VL - 44
SP - 512-7; discussion 517-8
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 5
ER -
